Patient Characteristics
| Characteristic | No. of patients* (n = 25) |
|---|---|
| Race | |
| Caucasian | 14 |
| African-American | 7 |
| Hispanic | 2 |
| Other | 2 |
| Prostatectomy findings | |
| Pathologic T stage | |
| pT1/T2 | 6 |
| pT3 | 16 |
| pT4 | 2 |
| pTx | 1 |
| Grade (Gleason Score) | |
| GS 6 | 5 |
| GS 7 | 14 |
| GS 8 | 2 |
| GS 9 | 2 |
| Uncharted | 2 |
| Margins | |
| Positive | 12 |
| Negative | 11 |
| Uncharted | 2 |
| Seminal vesicle invasion | |
| Positive | 6 |
| Negative | 18 |
| Uncharted | 1 |
| Extracapsular extension | |
| Yes | 17 |
| No | 7 |
| Uncharted | 1 |
| Pelvic lymph node involvement: | |
| Yes | 0 |
| No | 23 |
| Unsampled | 2 |
| Postprostatectomy course | |
| Postprostatectomy nadir (ng/mL) | |
| PSA ≤ 0.1 | 10 |
| 0.1 < PSA ≤ 0.2 | 2 |
| 0.2 < PSA ≤ 0.3 | 6 |
| 0.3 < PSA ≤ 0.5 | 1 |
| 0.5 < PSA ≤ 1.0 | 2 |
| 1.0 < PSA | 1 |
| Uncharted | 3 |
| Highest postprostatectomy PSA before RT consultation (ng/mL)† | |
| PSA ≤ 0.1 | 2 |
| 0.1 < PSA ≤ 0.2 | 3 |
| 0.2 < PSA ≤ 0.3 | 5 |
| 0.3 < PSA ≤ 0.5 | 3 |
| 0.5 < PSA ≤ 1.0 | 5 |
| 1.0 < PSA ≤ 2.0 | 5 |
| 2.0 < PSA | 2 |
| Uncharted | 0 |
| RIS findings | |
| Uptake only in prostate fossa | 23 |
| Prostate fossa and pelvic node uptake | 2 |
| Extrapelvic uptake | 0 |
| No uptake | 0 |
| Treatment information‡ | |
| Volume | |
| Whole pelvis initially | 2 |
| Prostate bed for entire duration | 23 |
| Prostate bed treatment technique | |
| 4-field | 2 |
| 6-field | 13 |
| IMRT | 10 |
| Final dose (Gy)§ | |
| 64.0 | 2 |
| 64.8 | 1 |
| 65.0 | 1 |
| 66.0 | 18 |
| 66.4 | 1 |
| 68.0 | 2 |